EGFR and colorectal carcinoma: In vitro study, cetuximab-resistant CRC cells showed a remarkable decrease in the level of EGFR and an enhanced role of Src kinase in collaboration with EGFR for supporting cell growth and survival [19], therefore oxaliplatin might decrease the activity of EGFR MAb.